In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Long-term follow-up of patients with refractory angina treated with transcutaneous electrical nerve stimulation

Session Poster session 1

Speaker Jesus Alvarez-Garcia

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : J Alvarez-Garcia (Barcelona,ES), R Serra (Barcelona,ES), A Ferrero-Gregori (Barcelona,ES), J Cinca (Barcelona,ES), X Garcia-Moll (Barcelona,ES)

Authors:
J. Alvarez-Garcia1 , R. Serra2 , A. Ferrero-Gregori1 , J. Cinca1 , X. Garcia-Moll1 , 1Hospital de la Santa Creu i Sant Pau, IIb-Sant Pau, CIBERCV, Universitat A, Cardiology - Barcelona - Spain , 2Hospital de la Santa Creu i Sant Pau, Anestesiology - Barcelona - Spain ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 192

Background: Transcutaneous electrical nerve stimulation (TENS) improves quality of life of patients with refractory angina (RA). However, the natural history and predictors of adverse outcome in series with long follow-up are not well-known.

Purpose: To describe the clinical profile and long-term prognosis of patients with refractory angina with TENS.

Methods: A cohort of 159 RA patients with TENS was prospectively followed for a median of 4.4 years. Baseline characteristics were compared with the last visit at follow-up at a RA clinic. Mixed-effects logistic regressions were used to identify independent predictors of mortality.

Results: Clinical data are summarized in table. Mean age was 70.1 years and 59.7% were male. The mean number of vessels disease was 2.6, and the mean evolution of ischemic heart disease was 13.1 years. As compared with baseline, there was a significant reduction in the number of chest pain episodes per week (10.1 vs. 3.1, p<0.001) and consumption of sublingual nitrates per week ((9.5 vs. 2.6, p<0.001). 31 patients died (19.5%) and 39 (24.5%) were readmitted for acute coronary syndrome. The independent predictors of all-cause mortality were age (OR 1.08; CI 95%: 1.03–1.13), peripheral artery disease (OR 3.16; CI 95%: 1.29–7.74), and treatment with statins (OR 0.43; CI 95%: 0.20–0.96).

Conclusion: Beneficial effects of TENS on reducing angina symptoms in patients with refractory angina persisted after a long-term follow-up.

Table 1
BaselineFollow-up visitp
Smokers, n (%)142 (89.3)14 (11.0)ns
Hypertension, n (%)94 (59.1)76 (59.7)ns
Dyslipidemia, n (%)90 (56.6)73 (57.0)ns
Diabetes mellitus, n (%)65 (40.9)52 (41.0)ns
Previous MI, n (%)79 (65.3)84 (66.0)ns
Previous PTCA, n (%)40 (34.5)55 (42.9)ns
Previous CABG, n (%)63 (52.5)66 (52.6)ns
Beta-blockers, %60.4%69.2%<0.001
Calcium blockers, %49.1%59.1%<0.001
Long acting nitrates, %54.7%74.8%<0.001
Antiplatelet therapy, %79.7%84.9%<0.001
Statins, %32.1%66%<0.00

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are